---
title: "Ulixacaltamide: Essential tremor"
description: "Formulary evidence on Ulixacaltamide in Essential tremor. Clinical evidence covers Essential3 study 1, Essential3 study 2, Essential1, PRAX-944-221, and PRAX-944-105. 188 evidence topics quoted from 77 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ulixacaltamide: Essential tremor

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Ulixacaltamide

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Essential tremor

<a id="topic-1.1.1-1"></a>

##### Summary

A population estimate placed US essential tremor prevalence at approximately 7.01 million people in 2012, whereas a separate analysis estimated 1.1 million US adults with diagnosed essential tremor in 2024. These estimates use different ascertainment approaches and do not establish a temporal decline. Reported burdens include impaired daily activities, depression, anxiety, falls, sleep disturbance, and caregiver assistance. One claims analysis reported annual all-cause healthcare costs of $17,560 per person with essential tremor in 2019 US dollars, including $2,233 attributed to essential tremor. In a clinic-based cohort, approximately 25% required care partners, with reported caregiving averaging 24 to 44 hours weekly.

Source: [Louis and Ottman (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4137360/); [Lin et al. (2025)](https://tremorjournal.org/articles/10.5334/tohm.1060); [Gerbasi et al. (2022)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.891446/full); [Dai et al. (2022)](https://jheor.org/article/37307-multiple-comorbidities-psychiatric-disorders-healthcare-resource-utilization-and-costs-among-adults-with-essential-tremor-a-retrospective-observati); [Gerbasi et al. (2025b)](https://tremorjournal.org/articles/10.5334/tohm.1046)

<a id="heading-1.1.2"></a>

#### 1.1.2 Ulixacaltamide Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

Essential3 Study 1 randomized 473 participants. At Day 56, mADL11 changed by -4.3 with ulixacaltamide and -1.7 with placebo in the mITT populations of 199 and 233 participants, respectively; the between-group difference was -2.57 points (95% CI, -3.62 to -1.53). Study 2 enrolled 238 participants and randomized 80 responders to continued treatment or placebo; 55% and 33%, respectively, maintained response. Drug-related adverse events led to discontinuation in 63 of 233 ulixacaltamide recipients (27.0%) versus 4 of 234 placebo recipients (1.7%) in Study 1, and 65 of 231 ulixacaltamide recipients (28.1%) in Study 2. Essential1 did not meet its primary endpoint (p=0.126); its TETRAS-ADL secondary result was nominally significant (p=0.026).

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/); [Farmer et al. (2026a)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-005412.html); [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/); [Shtilbans et al. (2026)](https://praxismedicines.com/aan2026-17-003/); [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Ulixacaltamide

No evidence found.

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

The phase 3 evidence supports short-term improvement in daily functioning versus placebo and maintenance of benefit during randomized withdrawal among selected responders. Treatment discontinuations, differential inclusion in the Study 1 mITT analysis, and the responder-enriched Study 2 design limit interpretation. Essential1 did not meet its primary endpoint. Ulixacaltamide remains investigational; the reported FDA target action date is January 29, 2027, rather than an approval date. Comparative effectiveness against established therapies and product-specific economic value remain undetermined in the evidence collected here.

Source: [Brillman et al. (2026a)](https://praxismedicines.com/aan2026-17-002/); [Farmer (2026b)](https://praxismedicines.com/aan2026-pl5-001/); [Shtilbans et al. (2026)](https://praxismedicines.com/aan2026-17-003/); [Praxis Precision Medicines Essential1 topline results announcement (2023)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-topline-results-essential1); [Praxis Precision Medicines AAN 2026 Annual Meeting page (2026)](https://praxismedicines.com/2026-aan-annual-meeting/); [Praxis Precision Medicines NDA acceptance announcement (2026)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-acceptance-new-drug)

## Related pages
- [Ulixacaltamide in Essential tremor: Terms and abbreviations](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations.md)
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary.md)
- [Ulixacaltamide in Essential tremor: Product information and disease description](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description.md)
- [Ulixacaltamide in Essential tremor: Clinical evidence](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence.md)
- [Ulixacaltamide in Essential tremor: Economic information and modeling report](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics.md)
- [Ulixacaltamide in Essential tremor: References](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references.md)
- [Ulixacaltamide in Essential tremor: prevalence by geography](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence.md)
- [Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses.md)
